Acadia Pharmaceuticals | ACAD - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
ALKERMES USD -48.28M 37.33M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cara Therapeutics USD -5.94M 3.55M 2025-09
Corcept Therapeutics USD -49.6M 54.09M 2026-03
Cytokinetics USD -181.23M 2.86M 2026-03
Eisai JPY -10.31B 30.35B 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Incyte USD 324.17M 59.7M 2026-03
J&J USD 6.62B 1.03B 2026-03
Moderna USD -1.39B 531M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Pfizer USD 4.99B 340M 2026-03
Prothena USD -27.21M 12.55M 2025-12
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03